157 related articles for article (PubMed ID: 31038558)
1. EVALUATING MMP-2 AND TGFß-RI EXPRESSION IN CIRCULATING TUMOR CELLS OF PANCREATIC CANCER PATIENTS AND THEIR CORRELATION WITH CLINICAL EVOLUTION.
Gasparini-Junior JL; Fanelli MF; Abdallah EA; Chinen LTD
Arq Bras Cir Dig; 2019; 32(2):e1433. PubMed ID: 31038558
[TBL] [Abstract][Full Text] [Related]
2. Molecular detection of epithelial-mesenchymal transition markers in circulating tumor cells from pancreatic cancer patients: Potential role in clinical practice.
Zhao XH; Wang ZR; Chen CL; Di L; Bi ZF; Li ZH; Liu YM
World J Gastroenterol; 2019 Jan; 25(1):138-150. PubMed ID: 30643364
[TBL] [Abstract][Full Text] [Related]
3. A prospective examination of circulating tumor cell profiles in non-small-cell lung cancer molecular subgroups.
Lindsay CR; Faugeroux V; Michiels S; Pailler E; Facchinetti F; Ou D; Bluthgen MV; Pannet C; Ngo-Camus M; Bescher G; Caramella C; Billiot F; Remon J; Planchard D; Soria JC; Besse B; Farace F
Ann Oncol; 2017 Jul; 28(7):1523-1531. PubMed ID: 28633480
[TBL] [Abstract][Full Text] [Related]
4. The prognostic and therapeutic implications of circulating tumor cell phenotype detection based on epithelial-mesenchymal transition markers in the first-line chemotherapy of HER2-negative metastatic breast cancer.
Guan X; Ma F; Li C; Wu S; Hu S; Huang J; Sun X; Wang J; Luo Y; Cai R; Fan Y; Li Q; Chen S; Zhang P; Li Q; Xu B
Cancer Commun (Lond); 2019 Jan; 39(1):1. PubMed ID: 30606259
[TBL] [Abstract][Full Text] [Related]
5. MIR-203A-3P AND MMP-2 PROTEINS ARE HIGHLY EXPRESSED IN CIRCULATING TUMOR CELLS FROM PATIENTS WITH PANCREATIC CARCINOMA.
Tarazona JGR; Abdallah EA; Flores BCT; Braun AC; Camillo CMC; Marchi FA; Ruano APC; Chinen LTD
Arq Bras Cir Dig; 2022; 34(4):e1628. PubMed ID: 35107490
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal marker and LGR5 expression levels in circulating tumor cells correlate with colorectal cancer prognosis.
Wang W; Wan L; Wu S; Yang J; Zhou Y; Liu F; Wu Z; Cheng Y
Cell Oncol (Dordr); 2018 Oct; 41(5):495-504. PubMed ID: 29949050
[TBL] [Abstract][Full Text] [Related]
7. High Expression of BCAR1 by Circulating Tumor Cells and Tumor Tissues Is Predictive of a Poor Prognosis of Early-Stage Lung Adenocarcinoma Potentially Due to Regulation of Epithelial-Mesenchymal Transition.
Jiang S; Mao C; Jiang B; Tan Q; Deng B
Technol Cancer Res Treat; 2020; 19():1533033820983086. PubMed ID: 33334252
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinase 1 and circulating tumor cells in early breast cancer.
Cierna Z; Mego M; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Cingelova S; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2014 Jun; 14():472. PubMed ID: 24972610
[TBL] [Abstract][Full Text] [Related]
9. Analysis of circulating tumour cell and the epithelial mesenchymal transition (EMT) status during eribulin-based treatment in 22 patients with metastatic breast cancer: a pilot study.
Horimoto Y; Tokuda E; Murakami F; Uomori T; Himuro T; Nakai K; Orihata G; Iijima K; Togo S; Shimizu H; Saito M
J Transl Med; 2018 Oct; 16(1):287. PubMed ID: 30342534
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of epithelial-mesenchymal transitioned circulating tumor cells in patients with resectable gastric cancer: Relevance to therapy response.
Li TT; Liu H; Li FP; Hu YF; Mou TY; Lin T; Yu J; Zheng L; Li GX
World J Gastroenterol; 2015 Dec; 21(47):13259-67. PubMed ID: 26715808
[TBL] [Abstract][Full Text] [Related]
11. Classification of circulating tumor cells by epithelial-mesenchymal transition markers.
Wu S; Liu S; Liu Z; Huang J; Pu X; Li J; Yang D; Deng H; Yang N; Xu J
PLoS One; 2015; 10(4):e0123976. PubMed ID: 25909322
[TBL] [Abstract][Full Text] [Related]
12. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma.
Poruk KE; Valero V; Saunders T; Blackford AL; Griffin JF; Poling J; Hruban RH; Anders RA; Herman J; Zheng L; Rasheed ZA; Laheru DA; Ahuja N; Weiss MJ; Cameron JL; Goggins M; Iacobuzio-Donahue CA; Wood LD; Wolfgang CL
Ann Surg; 2016 Dec; 264(6):1073-1081. PubMed ID: 26756760
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-to-mesenchymal transition leads to disease-stage differences in circulating tumor cell detection and metastasis in pre-clinical models of prostate cancer.
Lowes LE; Goodale D; Xia Y; Postenka C; Piaseczny MM; Paczkowski F; Allan AL
Oncotarget; 2016 Nov; 7(46):76125-76139. PubMed ID: 27764810
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and Therapeutic Significance of Circulating Tumor Cell Phenotype Detection Based on Epithelial-Mesenchymal Transition Markers in Early and Midstage Colorectal Cancer First-Line Chemotherapy.
Lu G; Lu Z; Li C; Huang X; Luo Q
Comput Math Methods Med; 2021; 2021():2294562. PubMed ID: 34777560
[TBL] [Abstract][Full Text] [Related]
15. Expression and clinical relevance of epithelial and mesenchymal markers in circulating tumor cells from colorectal cancer.
Zhao R; Cai Z; Li S; Cheng Y; Gao H; Liu F; Wu S; Liu S; Dong Y; Zheng L; Zhang W; Wu X; Yao X
Oncotarget; 2017 Feb; 8(6):9293-9302. PubMed ID: 28030836
[TBL] [Abstract][Full Text] [Related]
16. Epithelial-mesenchymal transition phenotypes of circulating tumor cells correlate with the clinical stages and cancer metastasis in hepatocellular carcinoma patients.
Chen J; Cao SW; Cai Z; Zheng L; Wang Q
Cancer Biomark; 2017 Dec; 20(4):487-498. PubMed ID: 28869439
[TBL] [Abstract][Full Text] [Related]
17. Characterisation of circulating tumour cell phenotypes identifies a partial-EMT sub-population for clinical stratification of pancreatic cancer.
Semaan A; Bernard V; Kim DU; Lee JJ; Huang J; Kamyabi N; Stephens BM; Qiao W; Varadhachary GR; Katz MH; Shen Y; San Lucas FA; Gascoyne P; Alvarez HA; Maitra A; Guerrero PA
Br J Cancer; 2021 Jun; 124(12):1970-1977. PubMed ID: 33785875
[TBL] [Abstract][Full Text] [Related]
18. Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients.
Kallergi G; Papadaki MA; Politaki E; Mavroudis D; Georgoulias V; Agelaki S
Breast Cancer Res; 2011 Jun; 13(3):R59. PubMed ID: 21663619
[TBL] [Abstract][Full Text] [Related]
19. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.
Lindsay CR; Le Moulec S; Billiot F; Loriot Y; Ngo-Camus M; Vielh P; Fizazi K; Massard C; Farace F
BMC Cancer; 2016 Feb; 16():168. PubMed ID: 26923772
[TBL] [Abstract][Full Text] [Related]
20. EpCAM-independent isolation of circulating tumor cells with epithelial-to-mesenchymal transition and cancer stem cell phenotypes using ApoStream® in patients with breast cancer treated with primary systemic therapy.
Le Du F; Fujii T; Kida K; Davis DW; Park M; Liu DD; Wu W; Chavez-MacGregor M; Barcenas CH; Valero V; Tripathy D; Reuben JM; Ueno NT
PLoS One; 2020; 15(3):e0229903. PubMed ID: 32214335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]